CO2017003487A2 - Composiciones que comprenden polipéptidos gdf15 modificados para trastornos metabólicos - Google Patents

Composiciones que comprenden polipéptidos gdf15 modificados para trastornos metabólicos

Info

Publication number
CO2017003487A2
CO2017003487A2 CONC2017/0003487A CO2017003487A CO2017003487A2 CO 2017003487 A2 CO2017003487 A2 CO 2017003487A2 CO 2017003487 A CO2017003487 A CO 2017003487A CO 2017003487 A2 CO2017003487 A2 CO 2017003487A2
Authority
CO
Colombia
Prior art keywords
compositions
metabolic disorders
gdf15 polypeptides
modified gdf15
disorder
Prior art date
Application number
CONC2017/0003487A
Other languages
English (en)
Spanish (es)
Inventor
Raj Haldankar
Wenyan Shen
Darrin Lindhout
Hugo Matern
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of CO2017003487A2 publication Critical patent/CO2017003487A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CONC2017/0003487A 2014-10-31 2017-04-10 Composiciones que comprenden polipéptidos gdf15 modificados para trastornos metabólicos CO2017003487A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073737P 2014-10-31 2014-10-31
US201562244604P 2015-10-21 2015-10-21
PCT/US2015/058111 WO2016069921A1 (en) 2014-10-31 2015-10-29 Compositions and methods of use for treating metabolic disorders

Publications (1)

Publication Number Publication Date
CO2017003487A2 true CO2017003487A2 (es) 2017-09-11

Family

ID=55851475

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0003487A CO2017003487A2 (es) 2014-10-31 2017-04-10 Composiciones que comprenden polipéptidos gdf15 modificados para trastornos metabólicos

Country Status (30)

Country Link
US (4) US9920118B2 (enExample)
EP (2) EP3212226B1 (enExample)
JP (1) JP6722175B2 (enExample)
KR (1) KR102672706B1 (enExample)
CN (2) CN115043945A (enExample)
AP (1) AP2017009828A0 (enExample)
AU (1) AU2015339130C1 (enExample)
CL (1) CL2017000864A1 (enExample)
CO (1) CO2017003487A2 (enExample)
DK (1) DK3212226T3 (enExample)
DO (1) DOP2017000097A (enExample)
EA (1) EA036985B1 (enExample)
EC (1) ECSP17021754A (enExample)
ES (1) ES2799503T3 (enExample)
GT (1) GT201700072A (enExample)
IL (1) IL251066B (enExample)
MD (1) MD20170035A2 (enExample)
MX (1) MX357994B (enExample)
MY (1) MY186702A (enExample)
NI (1) NI201700042A (enExample)
PE (1) PE20171058A1 (enExample)
PH (1) PH12017500680A1 (enExample)
PL (1) PL3212226T3 (enExample)
PT (1) PT3212226T (enExample)
SG (1) SG11201702580PA (enExample)
SV (1) SV2017005420A (enExample)
TN (1) TN2017000113A1 (enExample)
TW (1) TWI703161B (enExample)
UA (1) UA121973C2 (enExample)
WO (1) WO2016069921A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113008A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP2950807B1 (en) 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
TN2016000578A1 (en) 2014-07-30 2018-04-04 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
EP3212226B1 (en) * 2014-10-31 2020-03-18 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP3229586B1 (en) 2014-12-10 2025-07-30 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
IL260937B2 (en) 2016-02-06 2024-07-01 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof
WO2017172260A1 (en) 2016-03-31 2017-10-05 Ngm Bioparmaceuticals, Inc. Binding proteins and methods of use thereof
MA45113A (fr) 2016-05-24 2019-04-10 Novo Nordisk As Composés mic-1 et leur utilisation
CA3203613A1 (en) * 2016-07-19 2018-01-25 Ibentrus, Inc. Bispecific proteins and methods for preparing same
AU2017312974B2 (en) * 2016-08-16 2024-03-21 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem Fab bispecific antibodies
EP3538124A4 (en) * 2016-11-13 2020-07-22 Imagine Pharma COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA
CA3045700A1 (en) * 2016-12-06 2018-06-14 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
CN111163795A (zh) 2017-09-10 2020-05-15 诺沃挪第克公司 用于治疗肥胖症的mic-1和glp-1
WO2019156565A1 (en) 2018-02-12 2019-08-15 Fast Forward Pharmaceuticals B.V. Improved antagonistic anti-human cd40 monoclonal antibodies
TWI724392B (zh) * 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
PE20201350A1 (es) 2018-04-09 2020-11-30 Amgen Inc Proteinas de fusion del factor de diferenciacion de crecimiento 15
US12060425B2 (en) 2018-05-03 2024-08-13 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
JP2021533743A (ja) 2018-08-10 2021-12-09 ノバルティス アーゲー Ｇｆｒａｌ細胞外ドメイン及び使用方法
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
AU2019368816B2 (en) 2018-10-22 2025-01-30 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
EP3934679A1 (en) * 2019-03-08 2022-01-12 Amgen Inc. Growth differentiation factor 15 combination therapy
AU2020260931B2 (en) * 2019-04-23 2023-08-24 Lg Chem, Ltd. Fusion polypeptide comprising Fc region of immunoglobulin and GDF15
AU2020318112C1 (en) * 2019-07-19 2024-09-26 Wuxi Xdc Singapore Private Limited Polypeptide complex for conjugation and use thereof
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
KR20210065057A (ko) * 2019-11-26 2021-06-03 주식회사유한양행 지속형 gdf15 융합 단백질 및 이를 포함하는 약학 조성물
CA3159979A1 (en) * 2019-12-11 2021-06-17 Yeonchul Kim Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation
CN111499764B (zh) * 2020-04-02 2022-02-08 北京翼方生物科技有限责任公司 一种具有促红细胞生成素活性的长效融合蛋白
CN111887828B (zh) * 2020-07-08 2021-05-07 中南大学湘雅医院 围术期患者非接触式生理信息监测装置、计算机设备和存储介质
DE102020122214B4 (de) 2020-08-25 2026-01-29 Kulzer Gmbh Verfahren und Vorrichtung zum Kürzen von Prothesenzähnen für Dentalprothesen
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
WO2025217523A1 (en) * 2024-04-12 2025-10-16 23Andme, Inc. Variant hinge and molecules comprising same

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6180602B1 (en) 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
WO1994003599A1 (fr) 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
JPH07250688A (ja) 1994-01-28 1995-10-03 Sagami Chem Res Center ＴＧＦ−βスーパーファミリー蛋白質をコードするヒト新規ｃＤＮＡ
JPH07258293A (ja) 1994-03-23 1995-10-09 Asahi Chem Ind Co Ltd 新規な蛋白質ならびにその製造方法
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
AU1830195A (en) 1994-12-15 1996-07-03 Human Genome Sciences, Inc. Prostatic growth factor
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0833912B1 (en) 1995-06-22 2009-02-25 St Vincent's Hospital Sydney Limited Novel tgf-beta like cytokine
US6524802B1 (en) 1996-03-29 2003-02-25 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-14
WO1998011224A1 (en) 1996-09-11 1998-03-19 Ortho-Mcneil Pharmaceutical,Inc Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
ZA981936B (en) 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
WO2000005259A1 (en) 1998-07-23 2000-02-03 Smithkline Beecham Corporation Secreted cysteine rich protein-6 (scrp-6)
WO2000014095A1 (en) 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US6974684B2 (en) 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE348164T1 (de) 1999-05-17 2007-01-15 Bioph Biotech Entw Pharm Gmbh Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilie
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US7572619B2 (en) 2000-03-22 2009-08-11 Octagene Gmbh Recombinant blood clotting factors
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
EP1914554B1 (en) 2000-04-20 2010-06-09 St Vincent's Hospital Sydney Limited Diagnostic assay involving macrophage inhibitory cytokine-1 (MIC-1)
WO2002020759A2 (en) 2000-09-08 2002-03-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
CA2433439A1 (en) 2000-12-29 2002-08-15 Curagen Corporation Proteins and nucleic acids encoding same
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
AU2002250293B2 (en) 2001-03-09 2007-10-11 Arnason, Barry G. Mr Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
HU229910B1 (hu) 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks A TALL-1-hez kötõdõ peptidek és rokon molekulák
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US20030053431A1 (en) 2001-09-10 2003-03-20 Lila Madour Method for performing handoff in a radio telecommunications network
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
US20060253913A1 (en) 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
US20040253207A1 (en) 2002-11-08 2004-12-16 Barnes-Jewish Hospital Methods and compositions for prostate epithelial cell differentiation
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
ES2518865T3 (es) 2004-04-13 2014-11-05 St Vincent's Hospital Sydney Limited Agente de inhibición de MIC-1
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1841452B8 (en) 2004-10-08 2014-06-11 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
PT1844337E (pt) 2005-01-24 2014-04-03 Pepscan Systems Bv Compostos ligantes, compostos imunogénicos e peptidomiméticos
JP2007258293A (ja) 2006-03-22 2007-10-04 Fuji Electric Holdings Co Ltd はんだ濡れ性評価装置およびはんだ濡れ性評価方法
HRP20160990T1 (hr) 2006-03-24 2016-10-07 Biogen Hemophilia Inc. Pc5 kao enzim obrade faktor ix propeptida
US8974748B2 (en) 2007-04-05 2015-03-10 Corning Incorporated Dual inlet microchannel device and method for using same
MX2008015263A (es) 2006-06-02 2008-12-17 Wyeth Corp Uso de proteinas y pepetidos de la superfamilia del factor beta transformador de crecimiento para purificacion y metodos terapeuticos.
US7754689B2 (en) 2006-06-02 2010-07-13 Wyeth Llc Finger-1 peptide analogs of the TGF-β superfamily
EP2052253A2 (en) 2006-07-26 2009-04-29 Pepscan Systems B.V. Immunogenic compounds and protein mimics
WO2008015254A2 (en) 2006-08-04 2008-02-07 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on gdf-15
CN101808672B (zh) 2007-04-25 2013-05-01 干细胞旋转股份公司 干细胞系、其应用以及培养方法
CA2720628A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
US8937153B2 (en) 2007-07-31 2015-01-20 Affibody Ab Compositions, methods and uses
EP2783698A1 (en) 2007-08-16 2014-10-01 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
US20100266707A1 (en) 2007-10-09 2010-10-21 Samuel Norbert Breit Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
WO2009052557A1 (en) 2007-10-22 2009-04-30 St Vincent's Hospital Sydney Limited Methods of prognosis
KR20100087344A (ko) 2007-10-29 2010-08-04 버지니아 테크 인터렉추얼 프라퍼티스, 인크. 돼지 ＤＣ-ＳＩＧＮ, ＩＣＡＭ－３ 및 ＬＳＥＣｔｉｎ 및 이의 용도
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2227696A1 (en) 2008-01-08 2010-09-15 Roche Diagnostics GmbH Means and methods for assessing the risk of patients presenting to emergency units based on gdf-15
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
KR20100132535A (ko) 2008-03-31 2010-12-17 글락소 그룹 리미티드 약물 융합체 및 컨주게이트
JP2011523051A (ja) 2008-05-20 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５
JP2011528115A (ja) 2008-07-14 2011-11-10 エフ．ホフマン−ラ ロシュ アーゲー 心不全を有する患者の診断、モニター及び治療の選択のためのマルチマーカーパネル
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
JP5444363B2 (ja) 2008-10-31 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 慢性腎疾患における予後判定の方法
MX2011004563A (es) 2008-10-31 2011-06-01 Centocor Ortho Biotech Inc Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico.
KR20100054711A (ko) 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
EP2211182A1 (en) 2009-01-16 2010-07-28 Roche Diagnostics GmbH Method for the assessment of severity of liver cirrhosis
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
WO2010093925A2 (en) 2009-02-12 2010-08-19 Stryker Corporation PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE
GB0902737D0 (en) 2009-02-19 2009-04-01 Univ Gent GDF15 as a differential marker for spondyloarthropathy
US8952130B2 (en) 2009-02-24 2015-02-10 The Salk Institute For Biological Studies Designer ligands of TGF-β superfamily
TWI560197B (en) 2009-05-05 2016-12-01 Amgen Inc Fgf21 mutants and uses thereof
MX2011013455A (es) 2009-07-08 2012-02-13 Amgen Inc Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3.
WO2011008956A2 (en) 2009-07-15 2011-01-20 Zirus, Inc. Mammalian genes involved in infection
WO2011050407A1 (en) 2009-10-28 2011-05-05 St Vincent's Hospital Sydney Limited Methods of diagnosing and prognosing colonic polyps
SI2496601T1 (sl) 2009-11-05 2017-09-29 F. Hoffmann-La Roche Ag Tehnike in sestavek za sekrecijo heterolognih polipeptidov
WO2011064758A2 (en) 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
SI2506871T1 (sl) 2009-11-30 2016-12-30 Janssen Biotech, Inc. Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami
US9212221B2 (en) 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
JP5791335B2 (ja) 2010-04-07 2015-10-07 花王株式会社 オルガノポリシロキサン化合物の製造方法
US20130202564A1 (en) 2010-04-09 2013-08-08 University Of Southern California Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration
EP2383571A1 (en) 2010-05-02 2011-11-02 Prof. Hess Medical Consulting GmbH Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer
EP2609427B1 (en) 2010-08-26 2015-01-21 Roche Diagnostics GmbH Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
JP6161541B2 (ja) * 2011-02-03 2017-07-12 ゾーマ テクノロジー リミテッド 細菌中の機能的タンパク質発現を向上させるための方法および物質
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
ES2608835T3 (es) 2011-04-13 2017-04-17 Bristol-Myers Squibb Company Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
JP5997151B2 (ja) 2011-06-30 2016-09-28 中外製薬株式会社 ヘテロ二量化ポリペプチド
WO2013003680A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
WO2013113008A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2013192388A1 (en) 2012-06-20 2013-12-27 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
WO2014000042A1 (en) 2012-06-27 2014-01-03 Prince Henry's Institute Of Medical Research COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS
BR112015002085A2 (pt) 2012-08-08 2017-12-19 Roche Glycart Ag proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção
CA2896076C (en) 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
EP2950807B1 (en) * 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) * 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
PE20151673A1 (es) 2013-03-15 2015-11-27 Genentech Inc POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
CN203123206U (zh) 2013-04-01 2013-08-14 宋艳丽 一种简易式一次性防污染无菌注射器
EP3027647A4 (en) * 2013-07-31 2017-01-04 Amgen Inc. Stabilization of fc-containing polypeptides
UA116665C2 (uk) 2013-07-31 2018-04-25 Емджен Інк. Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15)
TN2016000578A1 (en) 2014-07-30 2018-04-04 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
EP3212226B1 (en) 2014-10-31 2020-03-18 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
AU2020260931B2 (en) 2019-04-23 2023-08-24 Lg Chem, Ltd. Fusion polypeptide comprising Fc region of immunoglobulin and GDF15
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Also Published As

Publication number Publication date
IL251066A0 (en) 2017-04-30
SG11201702580PA (en) 2017-05-30
MD20170035A2 (ro) 2017-09-30
TWI703161B (zh) 2020-09-01
NZ730054A (en) 2023-11-24
EA036985B1 (ru) 2021-01-25
WO2016069921A1 (en) 2016-05-06
TW201625698A (zh) 2016-07-16
EA201790405A1 (ru) 2017-09-29
CN106687128A (zh) 2017-05-17
MX357994B (es) 2018-08-01
NI201700042A (es) 2017-05-04
CN115043945A (zh) 2022-09-13
EP3212226B1 (en) 2020-03-18
CL2017000864A1 (es) 2018-05-11
US20230312696A1 (en) 2023-10-05
US20180237514A1 (en) 2018-08-23
TN2017000113A1 (en) 2018-07-04
KR20170074852A (ko) 2017-06-30
MX2017005237A (es) 2017-06-30
DOP2017000097A (es) 2017-05-15
PL3212226T3 (pl) 2020-11-02
AP2017009828A0 (en) 2017-03-31
IL251066B (en) 2021-06-30
KR102672706B1 (ko) 2024-06-07
US11530260B2 (en) 2022-12-20
US12173060B2 (en) 2024-12-24
SV2017005420A (es) 2017-10-17
PH12017500680A1 (en) 2017-10-09
PT3212226T (pt) 2020-06-22
US10562965B2 (en) 2020-02-18
MY186702A (en) 2021-08-11
AU2015339130C1 (en) 2021-03-18
CA2961587A1 (en) 2016-05-06
BR112017005986A2 (pt) 2017-12-19
PE20171058A1 (es) 2017-07-21
GT201700072A (es) 2018-11-27
ECSP17021754A (es) 2017-05-31
UA121973C2 (uk) 2020-08-25
CN106687128B (zh) 2022-05-10
AU2015339130A1 (en) 2017-04-06
EP3212226A1 (en) 2017-09-06
DK3212226T3 (da) 2020-06-15
EP3701969A1 (en) 2020-09-02
US20160120999A1 (en) 2016-05-05
EP3212226A4 (en) 2018-04-11
US20200140536A1 (en) 2020-05-07
JP6722175B2 (ja) 2020-07-15
US9920118B2 (en) 2018-03-20
AU2015339130B2 (en) 2020-06-25
ES2799503T3 (es) 2020-12-18
JP2017538395A (ja) 2017-12-28

Similar Documents

Publication Publication Date Title
ECSP17021754A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
DOP2017000025A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
DOP2017000124A (es) Agonistas parciales del receptor de insulina
MX2017013178A (es) Terapia de combinacion para cancer.
TWD174690S (zh) 自行車座墊之部分（四）
MY202967A (en) Semaglutide in cardiovascular conditions
MX386150B (es) Tasimelteon para tratar el síndrome de smith-magenis.
MX379289B (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
MX378112B (es) Anticuerpos que potencian el factor h y sus usos.
MX383561B (es) Composiciones y kits para usarse en el tratamiento de un sujeto con síntomas de accidente cerebrovascular o infarto agudo de miocardio (iam).
ECSP17039183A (es) Agonistas parciales del receptor de insulina